Firm
Emma Green, partner at Bird & Bird, shares why the Iceland v Iceland dispute could prompt businesses and lawyers to think differently about brand enforcement
Practitioners have welcomed extended funding of the specialist police unit until 2029, while the UKIPO says it is exploring increased scale
Abion says integration with Baylos marks an important step in the company’s international expansion plans
Law firm mergers have the potential to reshape IP teams, and partners who were at the coalface of previous tie-ups say early coordination and flexibility can make the difference
Sponsored
Sponsored
-
Sponsored by Berken IPMaría Aurora García of Berken IP examines how Argentine courts are using dynamic injunctions to tackle illegal sports streaming, particularly in the context of major events such as the football World Cup -
Sponsored by Bird & BirdAnnika Lückemann and Jan van Dieck of Bird & Bird analyse the Unified Patent Court’s opening ruling concerning a supplementary protection certificate, highlighting procedural peculiarities, urgency considerations, and possible implications for pharmaceutical originator-generic disputes
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Parth Bajaj of RNA, Technology and IP Attorneys analyse new obligations concerning synthetically generated information, accelerated takedown provisions, and safe harbour implications amid rising SGI-driven scams
-
Sponsored by Tilleke & GibbinsLoc Xuan Le of T&G Law Firm LLC (TGVN), the local associate firm of Tilleke & Gibbins, outlines key amendments to Vietnam’s Law on Intellectual Property concerning AI use of protected IP objects
-
Sponsored by Tilleke & GibbinsWiramrudee (Pink) Mokkhavesa and Tanapong Pongburanakit of Tilleke & Gibbins say Thai courts’ evolving approach to criminal intellectual property damages enables brand owners to enhance return on investment in raids and avoid civil litigation
-
Sponsored by Wanhuida Intellectual PropertyXiaoping Wu and Jicheng Yang of Wanhuida Intellectual Property analyse an invalidation decision that addresses how dosage and administration features affect the inventiveness assessment of pharmaceutical use claims in China
